Trial Profile
A Phase 1b/2, Single-arm, Open-label, Multi-center Study of MP0250 in Combination With Osimertinib in Patients With EGFR-mutated Non-squamous Non-small Cell Lung Cancer (NSCLC) Pretreated With Osimertinib
Status:
Discontinued
Phase of Trial:
Phase I/II
Latest Information Update: 27 Mar 2023
Price :
$35
*
At a glance
- Drugs MP 0250 (Primary) ; Osimertinib
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- Sponsors Molecular Partners AG
- 27 May 2020 Status changed from suspended to discontinued.
- 09 May 2019 According to a Molecular Partners AG media release, the company has suspended enrollment of new patients in this trial following observation of adverse events in the kidney in this study leading to a partial clinical hold. The company is working with the FDA to lift the hold by examining the relationship between MP0250 treatment and risk of kidney injury.
- 09 May 2019 Status changed from active, no longer recruiting to suspended, according to a Molecular Partners AG media release.